Recent advances in antiretroviral therapy and HIV infection monitoring

Intervirology

Volumn 40, Issue 5-6, 1997, Pages 304-321

  Schmit, Jean Claude ^a,b   Weber, Bernard ^c,d  

^a Centre Hospitalier de Luxembourg   (Germany)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c Lab Reunis Kutter Lieners Hastert   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antiretroviral therapy; Dideoxynucleoside analogues; Drug resistance; Nonnucleoside reverse transcriptase inhibitors; Protease inhibitors; Viral load

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PHENOTYPE; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 2642640455     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150564     Document Type: Article

References (114)

1. Piatak M, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk K-C, Hahn BH, Shaw GM, Lifson JD: High levels of HIV-I in plasma during all stages of infection determined by competitive PC'R, Science 1993:259:1749-1754.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature 1995;373:123-126.
3. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demcter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Dcyton LR, Choda-kewitz JA, Fischl MA: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, N Engl J Med 1997:337:725-733.
4. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Rcichman RC, Hooper C, Corey L: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine, N Engl J Med 1996:334:1011-1017.
5. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzales C, McMahon D, Richman DD, Valentine FT, Jonas L, Mcibohm A, Emini EA, Chodakcwitz JA: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy, N Engl J Med 1997:337:734-739.
6. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma, Science 1996:272:1167-1170.
7. Jacobo-Molina A, Ding J, Nanni RG, Clark AD, Lu X, Tantillo C, Williams RL, Kramer G, Ferris AL, Clark P, Hizi A, Hughes SH, Arnold E: Crystal structure of human immunodeficiency virus type I reverse transcriptase com-plexed with double-stranded DNA at 3.0 &resolution shows bent DNA, Proc Natl Acad Sci USA 1993:90:6320-6324.
8. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Lecdom JM: The efficacy of azidothvmidine (AZT) in the treatment of patients with AIDS and AIDS-related complex, N Engl J Med 1987:317:185-191.
9. Barditch-Crovo P, Toole J, Hendrix CW, Cun-dv KC, Ebcling D, JatTc HS, Lietman PS: Antihuman immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adcfovir dipivoxil (9-(2-(bis-pivaloxymethyl)-phospho-nylmcthoxvjadenine in HIV-infected patients, J Infect Dis 1997;176:406-413.
10. Harrigan R, Stone C, Griffin P, Bloor S, Tisdale M, Larder B: Antiretroviral activity and resistance profile of the carbocyclic nucleoside HIV reverse transcriptase inhibitor 1592U89; in Fourth Conference on Retroviruses and Opportunistic Infections, Washington, 1997.
11. 3: in Fourth Conference on Retroviruses and Opportunistic Infections, Washington, 1997.
12. lnfektionsepidemiologischc Forschung: Update zur antiretroviralcn Therapic, Berlin, Robert Koch Institut, 1997. vol 2. pp 83-85.
13. De Clercq E: Broad spectrum anti-DNA virus and anti-retrovirus activity of phosphonylme-thoxyalkylpurincs and -pyrimidines, Biochem Pharmacol 1991:42:963-972.
14. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benvcnistc RE, Black R: Prevention of SIV infection in macaques by (R)-9 - (2-phosphonylmethoxypropyl)adenine, Science 1995;270:1197-1199.
15. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopntan JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Nusinoff-Lehrman S: The toxicity of azidothvmidine (AZT) in the treatment of patients with AIDS and AIDS-related complex, N Engl J Med 1987:317:192-197.
16. Schinazi RF, Larder BA, Mellors JW: Mutations in retroviral genes associated with drug resistance, Antiviral News 1996:4:95-107.
17. Soriano V, Dietrich U, Villalba N, Immeiman A, Gil-Aguado A, Echevarria S, Clotct B, Oca-na I, Santamaria JM, Bouza E, Barona V, Gatell JM, Gonzalcz-Lahoz J: Lack of emergence of genotypic resistance to stavudinc after 2 years of monotherapy, AIDS 1997; 11:696-697.
18. Tisdale M, Kemp SD, Parray NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type I resistant to 3'-thiacytidine inhibitors due to a mutation in the YMMD region of reverse transcriptase, Proc Natl Acad Sci USA 1993:90:5653-5656.
19. Demctcr LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondclis P, Reichman RC: Development of zidovudine resistance mutations in patients receiving prolonged didanosinc monotherapy, J Infect Dis 1995;172:1480-1485.
20. Mayers DL, Japour AJ, Arduino JM, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Cruntpacker CS, McLeod GX: Dideoxynu-clcoside resistance emerges with prolonged zidovudine monotherapy, Antimicrob Agents Chemother 1994:38:307-314.
21. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichclder-fer PS, Coombs RW, Cruntpacker CS, Kahn JO: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy, AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group, Ann Intern Med 1995:122: 401-408.
22. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy, Science 1995:269:696-699.
23. Schmit J-C, Martinez-Picado J, Ruiz L, Tural C, VanLacthcm K, Cabrera C, Ibanez A, Puig T, Witvrouw M, Clotet B, Dcsmytcr J, Dc Clercq E, Vandamme A-M: Evolution of HIV drug resistance in zidovudine (ZDV)/zalcita-binc (ddC) - and ZDV/didanosine (ddl) - experienced patients receiving lamivudine (3TC) containing combination therapy, Antiviral Therapy, in press.
24. Nijhuis M, Schuurman R, de Jong D, van Lecuwen R, Lange J, Danner S, Kculen W, de Groot T, Boucher CAB: Lamivudine-resistani human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-rcsistant to zidovudine in vivo, J Infect Dis 1997;176:398-405.
25. Shirasaka T, Yarchoan R, O'Brien MC, Hus-son RN, Anderson BD, Kojima E, Shimada T, Broder S, Mitsuya H: Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidinc, dideoxv-cytidinc, and dideoxyinosine: an in vitro comparative study, Proc Natl Acad Sci USA 1993: 90:562-566.
26. Shafer RW, Kozal MJ, Winters MA, Iversen AKN, Katzenstcin DA, Ragni MV, III WAM, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S, Merigan TC: Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations, J Infect Dis 1994:169:722-729.
27. Schmit J-C, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, VanRemoortel B, Wit-vrow M, Balzarini J, Desmyter J, De Clercq E, Vandamme A-M: Multiple drug resistance in nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type I patient strain, J Infect Dis 1996:174: 962-968.
28. Schmit J-C, Ruiz L, Hermans P, Sonnerborg A, Leal M, Harrer T, Clotct B, Sprecher S, Arendt V, Lisscn E, Witvrouw M, Desmyter J, De Clercq E, Vandamme A-M: Multiple dideoxy-nucleoside analog resistant (MddNR) HIV-1 strains from European patients, submitted.
29. Ding J, Das K, Tantillo C, Zhang W, Clark A, Jcsscn S, Lu X, Hisou Y, Jacobo-Molina A, Andrics K, Pauwels R, Moereels H, Koymans L, Janssen P, Smith R, Kocpke MK, Michejda C, Hughes S, Arnold E: Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor o-APA R 95845 at 2.8 A resolution, Structure 1995;3:365-379.
30. Checscman SH, Havlir D, McLaughlin MM, Grecnough TC, Sullivan JL, Hall D, Hattox SE, Spcctor SA, Stein DS, Myers M, Richman DD: Phase l/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus, J AIDS 1995:8:141-151.
31. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Grecnough TC, Sullivan JL, Hall D, Myers M, Lantson M, Richman DD: High-dose nevirapine: Safety, pharmacokinetics, antiviral effect in patients with human immunodeficiency virus infection, J Infect Dis 1995:171:537-545.
32. Olmsted RA, Slade DE, Kopta LA, Poppe SM, Poel TJ, Newport SW, Rank KB, Biles C, Morgc RA, Ducweke TJ, Yagi Y, Romero DL, Thomas RC, Sharma SK, Tarplcy WG: (Alky-lamino)piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1 IIIB with reduced replication phcnotvpcs, J Virol 1996:70:3698-3705.
33. Pauwels R, Andries K, Debyscr Z, Daele PV, Schols D, Stoffels P, Vreese KD, Woestcn-borghs R, Vandamme A-M, Janssen CGM, Anne J, Cauwenbcrgh G, Desmyter J, Hey-kants J, Janssen MAC, De Clercq E, Janssen PAJ: Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of a-aniiinophcnylacetamide derivatives targeted at HIV-1 reverse transcriptase, Proc Natl Acad Sci USA 1993:90:1711-1715.
34. Staszewski S, Miller V, Rehmet S, Stark T, De Cree J, De Brabandcr M, Peelers M, Andrics K, Moeremans M, Dc Raevmaeker M, Pearce G, Van Den Brocck R, Vcrbiest W, Stoffels P: Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1 infected patients, AIDS 1996:10:F1-F7.
35. CAESAR-Coordinating-Committee: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial, Lancet 1997:349:1413-1421.
36. Baba M, Tanaka H, De Clercq E, Pauwels R, Balzarini J, Schols D, Nakashima H, Perno CF, Walker RT, Miasaka T: Highly specific inhibition of human immunodeficiency virus type I by a novel series of 6-substituted acyclouridinc derivative, Biochem Biophys Res Commun 1989:165:1375-1381.
37. Balzarini J, Brouwer WG, Felauer EE, De Clereq E, Karlsson A: Activity of various thio-carboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains, Antiviral Res 1995:27:219-236.
38. Buckheit RW, Hollingshead M, Stinson S, Flia-kas-Boltz V, Pallansch LA, Robertson J, Decker W, Elder C, Borgcl S, Bonomi C, Shores R, Siford T, Malspeis L, Bader JP: Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781. a highly potent, orally bioavailablc nonnucleoside reverse transcriptase inhibitor of HIV type I, AIDS Res Hum Retrovirus 1997;13:789-796.
39. Kleim J P, Bender R, Kirsch R, Meiehsner C, Paessens A, Rosner M, Riibsamen-Waigmann H, Kaiser R, Wiehers M, Schnewcis KE, Winkler 1. Ricss G: Preclinical evaluation of HBY 097. a new nonnucleosidc reverse transcriptase inhibitor of human immunodeficiency virus type I replication, Antimicrob Agents Chemother 1995;39:2253-2257.
40. Riibsamcn-Waigmann H, Huguenel E, Paessens A, Kleim J-P, Wainberg MA, Shah A: Second-generation non-nucleoside reverse transcriptase inhibitor HBY097 and HIV-1 viral load, Lancet 1997:349:1517.
41. Duewcke TJ, Pushkarskaya T, Poppe SM, Swa-ncy SM, Zhao JQ, Chen 1SY, Stevenson M, Tarpley WG: A mutation in reverse transcriptase of bis(hetcroaryl)piperazinc-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors, Proc Natl Acad Sci USA 1993: 90:4713-4717.
42. Kleim J-P, Rosber M, Winkler I, Paessens A, Kirsch R, Hsiou Y, Arnold E, Riess G: Selective pressure of a quinoxaline nonnucleosidc inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-I replication results in the emergence of nucleoside RT-inhibitor-specific (RT Lcu-74-> Val or lie and Val-75 ->Leu or lie) HIV-I mutants, Proc Natl Acad Sci USA 1996:93:34-38.
43. De Clercq E, Balzarini J: Knocking out human immunodeficiency virus through non-nuclco-side reverse inhibitors used as single agents or in combinations: A paradigm for the cure of AIDS, Farmaco 1995;50:735-747.
44. Deeks SG, Smith M, Holodniy M, Kahn JO: HiV-1 protcase inhibitors, A review for clinicians, JAMA 1997;277:145-153.
45. Lea AP, Faulds D: Ritonavir, Drugs 1996:52: 541-546.
46. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, Gil Aguado A, Lomas JGD, Delgado R, Borleffs JCC, Hsu A, Valdes JM, Boucher CAB, Cooper DA: A short-term study of the safety, pharmakincties, and efficacy of ritonavir, an inhibitor of HIV-1 protease, N Engl J Med 1995;333:1528-1533.
47. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattlcr F, La Marca A, Leonard JM, Ho DD: A preliminary study of ritonavir, an inhibitor of HIV-1 pro-tease, to treat HIV-1 infection, N Engl J Med 1995:333:1534.
48. Laurence J, Schapiro J, Pesano R, Winters M, Cain P, Winslow D, Merigan TC: Clinical response and genotypic resistance patterns of sequential therapy with nelfinavir followed by indinavir plus nevirapine in saquinavir/reverse transcriptase inhibitor-experienced patients: in International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St, Petersburg, Fla, 1997.
49. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Bruckhardl J, Burger HU, Brag-man K, Pinching AJ, Weber JN: Safety and activity of saquinavir in HIV infection, Lancet 1995:345:952-955.
50. Noble S, Faulds D: Saquinavir, A review of its pharmacology and clinical potential in the management of HIV infection, Drugs 1996;52: 93-112.
51. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC: The effect of high-dosc saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients, Ann Intern Med 1996;124:1039-1050.
52. Kempf DJ, Marsh KC, Kumar G, Rogrigucs AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir, An-timicrob Agents Chemother 1997:41:654-660.
53. Chen C, Niu P, Kati W, Norbeck D, Sham H, Kempf D, Kohlbrenncr W, Plattner J, Leonard J, Molla A: Activity of ABT-378 against HIV protease containing mutations conferring resistance to ritonavir: in 4th Conference on Rctro-virology and Opportunistic Infections, Washington, 1997.
54. Zhang YM, Imamichi I, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP: Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites, J Virol 1997; 71:6662-6670.
55. Molla A, Korneyeva M, Gao Q, Vasavandonda S, Schipper PJ, Mo HM, Markowitz M, Cher-nyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CAB, Leonard JM, Norbeck DW, Kempf DJ: Ordered accumulation of mutations in 11IV protcase confers resistance to ritonavir, Nat Med 1996:2:760-766.
56. Condra JH, Schleif WA, Blahy OM: In vitro emergence of HIV-1 variants resistant to multiple protcase inhibitors, Nature 1995:374:569-571.
57. Schmit J-C, Ruiz L, Clolct B, Raventos A, Tor J, Leonard J, Dcsmvter J, De Clcrcq E, Van-dammc A-M: Resistance-related mutations in the HIV-1 protease gene of patients treated for I year with the protcasc inhibitor ritonavir (ABT-538), AIDS 1996:10:995-999.
58. Bjomdal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fcnyo EM: Coreceptor usage of primary human immunodeficiency virus type I isolates varies according to biological phenotype, J Virol 1997;71:7478-7487.
59. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farbcr C-M, Saragosti S, Lapou-meroulie C, Cognaux J, Forceille C, Muylder-mans G, Verhofstede C, Burtonboy G, Georges M, Irnai T, Rana S, Yi Y, Smyth RJ, Collman RG, Dorns RW, Vassart G, Parmentier M: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chcmokine receptor gene, Nature 1996:382: 721-724.
60. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burckhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996:381:661-666.
61. De Clcrcq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, Balzarini J, De-bvscr Z, Murrer BA, Schwartz D, Thornton D, Bridgcr G, Flicker S, Henson G, Abrams M, Picker D: Potent and selective inhibition of human immunodeficiency virus (HIV)-l and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event, Proc Natl Acad Sci USA 1992:89:5286-5290.
62. Schols D, Struyf S, Van Damme J, Estc JA, Henson G, De Clercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997: 186:1383-1388.
63. Este JA, DeVreese K, Witvrouw M, Schmit J-C, Vandamme A-M, Anne J, Desmyter J, Henson GW, Bridger G, De Clereq E: Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res 1996: 29:297-307.
64. Vandevcide M, Witvrouw M, Schmit J-C, De Clereq E, Tassignon J-P: ADA, a potential anti-HIV drug, AIDS Res Hum Retroviruses 1996: 12:567-568.
65. Rice WG, Turpin JA, Huang M, Clanton D, Buckheit RW, Covell DG, Wallqvist A, McDonnell NB, DeGuzman RN, Summers MF, Zalkow L, Bader JP, Haugwitz RD, Saus-ville EA: Azodicarbonamidc inhibits HIV-1 replication by targeting the nucleocapsid protein, Nat Med 1997:3:341-345.
66. Thomas M, Brady L: HIV intcgrase: A target for AIDS therapeutics, Trends Biotechno! 1997:15:167-172.
67. Cherepanow P, Este JA, Rando RF, Ojwang JO, Rcekmans G, Steinfeld R, David G, De Clercq E, DebyscrZ: Mode of interaction of G-quartets in the intcgrase of human immunodeficiency virus type I, Mol Pharmacol 1997:52: 771-780.
68. Keikawus A, Czcrwinska R, Schlole F, Fatken-heuer G, Jessen H, Moll A, Gehring P, Ulmer A, Hantedani P, McPherson A: A randomised, double-blind, dose-ranging phase II European study on the safety and efficacy of chronically administered butanoyl-castanospcrminc (MDL 28.574A) in HIV infected patients: in XIth International AIDS Conference, Vancouver, 1996.
69. Witvrouw M, Pauwels R, Vandamme A-M, Schols D, Rcymcn D, Yamamoto N, Desmyter J, De Clercq E: Cell type-specific anti-human immunodeficiency virus type I activity of the transactivation inhibitor Ro 5-3335. Antimi-crob Agents Chemother 1992:36:2628-2633.
70. Yantaguchi K, Papp B, Zhang D, Ali AN, Agra-wal S, Bvm RA: The multiple inhibitory mechanisms of GEM91. a gag anlisense phosphoro-thioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1997;13:545-554.
71. Zhang R, Yan J, Shahinian H, Amin G, Liu Z, Liu T, Saag MS, Jiang Z, Tcmsamani J, Marlin RR: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodcoxynu-cleotide phosphorothioatc (GEM91) in HIV-infected subjects, Clin Pharmacol Ther 1995: 58:44-53.
72. Abrams DI, Goldman AI, Launer C, Korwiek J, Neaton JD, Crane LR, Grodesky M, Wakefield S, Muth K, Komegay S, Cohn DL, Harris A, Luskin-Hawk R, Markowitz N, Sampson JH, Thompson M, Deyton L: A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection, N Eng! J Med 1994:330:657-662.
73. Schoolev RT, Ramirez-Ronda C, Lange JMA, Cooper DE, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan RP, Kinghorn I, Rooney HSJF, Group WRSC: Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or di-danosinc compared with zidovudine monotherapy, J Infect Dis 1996:173:1354-1366.
74. Fischl MA, Olson RM, Follansbce SE, Lalczari JP, Henry DH, Frame PT, Rcmick SC, Salgo MP, Lin AH, Nauss-Karol C, Liebcrman J, Soo W: Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy, Ann Intern Med 1993;118:762-769.
75. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, Hooper CJ, Kaplan LD, Volberding PA, Davis LG, Henrard DR, Weller S, Corey L: Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-I infection, Ann Intent Med 1993:119:786-793.
76. Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Reniick SC, Thompson M, MacArthur RD: Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine, Ann Intern Med 1994;120:360-368.
77. Gatell JM, Gonzalez-Lahoz J, Clotet B, An-tuncs F, Kasparova L, Gilaguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A: Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression, J Acquir Immun Defic SyndrHum Rctrovirol 1996;12:249-258.
78. Delta-coordinating-committee, Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine with zidovudine alone in HIV-infected individuals, Lancet 1996:348:283-291.
79. Wong JK, Gunthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, Kwok S, Emini E, Richman DD: Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure, Proc Natl Acad Sci USA 1997:94: 12574-12579.
80. Concorde-coordinalion-committee, Concorde: MRC/ARNS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection, Lancet 1994:343:871-881.
81. Kinloch-De-Loes S, Hirschel BJ, Hocn B, Cooper DA, Tindall B, Carr A, Saurat JH, Clu-nteck N, Lazzarin A, Mathiescn L, Perrin L: A controlled trial of zidovudine in primary human immunodeficiency virus infection, N Engl J Med 1995;333:408-413.
82. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montancr JSG, Richman DD: Antiviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Socicty-USA Panel, JAMA 1997:277:1962-1969.
83. BHIVA-Guidelincs-Co-ordinating-Commit-tee: British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals, Lancet 1997:349:1086-1092.
84. Fontaine E, Hemmcr R, Plesseria JM, Ninove D, Kirpach P, Schneider F, Schmit J-C: Drug resistance mutations in HIV-1 strains from treatment-naive patients (Luxembourg 1992-1997); in 12th World AIDS Conference, Geneva, 1998.
85. Centers-for-Disease-Control-and-Prevention, Update: Provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV, MMWR 1996:45: 468-472.
86. Vandamme A-M, Van Wijngacrdcn E, Van Vaerenbergh K, Van Lacthem K, De Vrocy V, Schmit J-C, Debyser Z, Stuyver L, De Clereq E: The use of fast genotypic HIV-1 drug-resis-tance tests in the decision on chemoprophylaxis after occupational exposure to HIV; in Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, 1997.
87. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, O’Sullivan MJ, Dyke RBV, Jimenez E, Rouzioux C, Flynn PM, Sullivan JL: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type I from mother to infant, Pediatric AIDS Clinical Trials Group Protocol 076 Study Group, N Engl J Med 1996;335:1621-1629.
88. Carpenter CCJ, Fisehl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA: Antiretroviral therapy for HIV infection in 1996. JAMA 1996:276: 146-154.
89. van Gcmen B, Kievits T, Schukkink R, van Strijp D, Malek LT, Sooknanan R, Huisman HG, Lens P: Quantification of HIV-1 RNA in plasma using NASBA during HIV-I primary infection, J Virol Methods 1993;43:177-188.
90. Schaker T, Collier AC, Hughes J, Shea T, Corey L: Clinical and epidemiologic features of primary HIV infection, Ann Intern Med 1996: 125:257-264.
91. O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AT, Luban N, Hatzakis A, Aledort LM, Rosenberg PS, Milev WJ, Kroner BL, Goederl JJ: Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study, JAMA 1996:276:105-110.
92. Hammer SM, Katzenstein DA, Hughes MD, Grundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter, AIDS Clinical Trials Group Study 175 Study Team, N Engl J Med 1996:335:1081-1090.
93. Alaeus A, Lidman K, Sonncrsborg A, Albert J: Subtype-specific problems with quantification of plasma HIV-1 RNA, AIDS 1997:1 1:54-75.
94. Vandamme A-M, Schmit J-C, Van Dooren S, Van Laethcm K, Gobbers E, Kok W, Goubau P, Witvrouw M, Peetermans W, DeClercq E, Des-mvtcr J: Quantification of HIV-I RNA in plasma: Comparable results with the NASBA amplification system and with the Amplicor Monitor test, J AIDS Hum Rctrovirol 1996:13:127-139.
95. Krivine A, Le Bourdelles S, Firtion G, Lcbon P: Viral kinetics in HIV-1 perinatal infection, Lancet 1997:350:493.
96. Shearer WT, Quinn TC, La Russa P, Lew JF, Mofcnson L, Almy S, Rich K, Handelsman E, Diaz C, Pagano M, Smeriglio V, Kalish LA: Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group, N Engl J Med 1997:336:1337-1342.
97. Pease AC, Solas D, Sullivan EJ: Light-generated oligonucleotide arrays for rapid DNA sequence analysis, Proc Natl Acad Sci USA 1994: 365:451-453.
98. Larder BA, Boucher CA: PCR detection of human immunodeficiency virus drug resistance mutations: in Pershing DH, Smith TF, Tenover FC, White TJ (eds): Diagnostic Molecular Microbiology: Principles and Applications, Washington, American Society for Microbiology, 1993. pp 527-533.
99. Vandamme A-M, Witvrouw M, Pannecou-que C, Balzarini J, Van Lacthcm K, Schmit J-C, Desmyter J, Dc Clereq E: Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs; in Kinchington D, Schinazi R (eds): Methods in Molecular Biology: Antiviral Testing, The Humana Press, Totowa, 1997.
100. Schmit J-C, Vanderlinden I, Ruiz L, Clotet B, Hermans P, Sprecher S, Arendt V, Peetermans W, Harrcr T, Vaira D, Desmyter J, De Clereq E, Vandamme A-M: Prevalence of multi-drug resistance to dideoxynucleoside (ddN) analogues in patients on ddN combination therapy: in Fifth International Workshop on HIV drug-resistance, Whistler 1996. Antiviral Tiler I996;suppl I, p 25.
101. Schmit J-C, Ruiz L, Stuyver L, VanLaethcm K, Vanderlinden I, Puig T, Rossau R, Des-myter J, Clereq ED, Clotet B, Vandamme A-M: Comparison of the LiPA HIV-I RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations J Virol Meth, in press.
102. Stuyver L, Wvseur A, Romboul A: Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene, Antimicrob Agents Chemother 1997;41:284-291.
103. Schneider F, Plesseria J-M, Stuyver L, Lambert C, Fontaine E, Kirpach P, Ninove D, Arendt V, Hemmcr R, Schmit J-C: LiPA HIV-1 RT predicts phenotypic zidovudine resistance in HIV-1 patients isolates; in Fifth Conference on Retroviruses and Opportunistic Infections, Chicago 1998.
104. Japour AJ, Mayers DL, Johnson VA, Ku-ritzkcs DR, Beckett LA, Arduino J-M, Lane J, Black RL, Reichcldcrfer PS, D'Aquila RT, Crumpacker CS: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates, Antimicrob Agents Chemother 1993; 37:1095-1101.
105. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy, Science 1989:243:1731-1734.
106. Pauwels R, Balzarini J, Baba M, Snocck R, Schols D, Herdewijn P, Desmyter J, Dc Clercq E: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds, J Virol Methods 1988: 20:309-321.
107. Chou TC: Relationships between inhibition constants and fractional inhibitions in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types of mechanisms of inhibition, Mol Pharmacol 1974; 10:235-247.
108. Shafer RW, Kozal MJ, Katzenstein DA, Lipil WH, Johnstone IF, Merigan TC: Zidovudine susceptibility testing of human immunodeficiency virus type I (HIV) clinical isolates, J Virol Methods 1993;41:297-310.
109. Kellam P, Larder BA: Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates, Antimicrob Agents Chemother 1994;38:23-30.
110. Maschera B, Furfine E, Blair ED: Analysis of resistance to human immunodeficiency virus type 1 protcasc inhibitors by using matched bacterial expression and proviral infection vectors, J Virol 1995:69:5431-5436.
111. Plesseria J-M, Schmit J-C, Fontaine E, Scr-vais J, Fournier P, Lambert C, Kirpach P, Ninove D, Arendt V, Staub T, Schneider F, Hemmer R: The recombinant virus assay (RVA) for reverse transcriptase and protease delects patient HIV-1 isolates resistant to multiple antiretroviral drugs; in Third European Conference on Experimental AIDS Research (ECEAR), Munich 1998.
112. Tan CK, Zhang KM, So AG: Functional characterization of RN'A-dependcnt DNA polymerase and RNase activities of a recombinant HIV reverse transcriptase, Biochemistry 1991:30:2651-2655.
113. Mouton Y, Alfandari S, Valctte M, Cartier F, Dcllamonica P, Humbert G, Lang JM, Mas-sip P, Mechali D, Leclercq P, Modai J, Portier H: Impact of protcasc inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres, Federation Nationale des Centres de Lutte contre le SIDA, AIDS 1997:11:F101-F105.
114. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmcycr R, Gallant J, Markowitz M, Ho DD, Richman DD, Sili-ciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science 1997;278:1295-1300.